BlueRock Therapeutics LP is a clinical-stage biotechnology company developing allogeneic, induced pluripotent stem cell (iPSC)-derived cellular therapies. Founded in 2016 by Bayer AG and Versant Ventures, it became a wholly owned subsidiary of Bayer in 2019. The company is headquartered in Cambridge, Massachusetts, with operations in the United States and Canada, including facilities in New York and Toronto.
BlueRock’s research focuses on neurological, cardiovascular, and immunology indications. Its lead program, bemdaneprocel (BRT-DA01), uses iPSC-derived dopaminergic neurons for the treatment of Parkinson’s disease. The company also advances additional iPSC-based platforms and invests in GMP manufacturing and process development to support scalable, quality-controlled production of cell therapies.
Investigational iPSC-derived cell therapy for primary photoreceptor diseases receives orphan status across multiple inherited retinal disorder indications; being tested in a Phase 1/2a trial.
